[1]
Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, Goldberg JM, Khatcheressian JL, Leighl NB, Perkins CL, Somlo G, Wade JL, Wozniak AJ, Armitage JO, American Society of Clinical Oncology. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Oct 1:33(28):3199-212. doi: 10.1200/JCO.2015.62.3488. Epub 2015 Jul 13
[PubMed PMID: 26169616]
Level 1 (high-level) evidence
[2]
Hankey KG, Farese AM, Blaauw EC, Gibbs AM, Smith CP, Katz BP, Tong Y, Prado KL, MacVittie TJ. Pegfilgrastim Improves Survival of Lethally Irradiated Nonhuman Primates. Radiation research. 2015 Jun:183(6):643-55
[PubMed PMID: 26035709]
[3]
Yang BB, Kido A. Pharmacokinetics and pharmacodynamics of pegfilgrastim. Clinical pharmacokinetics. 2011 May:50(5):295-306. doi: 10.2165/11586040-000000000-00000. Epub
[PubMed PMID: 21456630]
[4]
Yang BB, Morrow PK, Wu X, Moxness M, Padhi D. Comparison of pharmacokinetics and safety of pegfilgrastim administered by two delivery methods: on-body injector and manual injection with a prefilled syringe. Cancer chemotherapy and pharmacology. 2015 Jun:75(6):1199-206. doi: 10.1007/s00280-015-2731-x. Epub 2015 Apr 17
[PubMed PMID: 25894719]
[5]
Kosaka Y, Rai Y, Masuda N, Takano T, Saeki T, Nakamura S, Shimazaki R, Ito Y, Tokuda Y, Tamura K. Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2015 Apr:23(4):1137-43. doi: 10.1007/s00520-014-2597-1. Epub 2015 Jan 10
[PubMed PMID: 25576433]
Level 1 (high-level) evidence
[6]
Kirshner JJ, McDonald MC 3rd, Kruter F, Guinigundo AS, Vanni L, Maxwell CL, Reiner M, Upchurch TE, Garcia J, Morrow PK. NOLAN: a randomized, phase 2 study to estimate the effect of prophylactic naproxen or loratadine vs no prophylactic treatment on bone pain in patients with early-stage breast cancer receiving chemotherapy and pegfilgrastim. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2018 Apr:26(4):1323-1334. doi: 10.1007/s00520-017-3959-2. Epub 2017 Nov 16
[PubMed PMID: 29147854]
Level 1 (high-level) evidence
[7]
Dadla A, Tannenbaum S, Yates B, Holle L. Delayed hypersensitivity reaction related to the use of pegfilgrastim. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 2015 Dec:21(6):474-7. doi: 10.1177/1078155214542493. Epub 2014 Jul 3
[PubMed PMID: 24993705]
[8]
Wolff AC, Jones RJ, Davidson NE, Jeter SC, Stearns V. Myeloid toxicity in breast cancer patients receiving adjuvant chemotherapy with pegfilgrastim support. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006 May 20:24(15):2392-4; author reply 2394-5
[PubMed PMID: 16710041]
[9]
Riley LK, Rupert J. Evaluation of Patients with Leukocytosis. American family physician. 2015 Dec 1:92(11):1004-11
[PubMed PMID: 26760415]
[10]
Rechner I, Brito-Babapulle F, Fielden J. Systemic capillary leak syndrome after granulocyte colony-stimulating factor (G-CSF). The hematology journal : the official journal of the European Haematology Association. 2003:4(1):54-6
[PubMed PMID: 12692521]
[11]
Riu G, Estefanell A, Nomdedeu M, Creus N. Overdose of pegfilgrastim: case report. International journal of clinical pharmacy. 2012 Oct:34(5):690-2. doi: 10.1007/s11096-012-9653-z. Epub 2012 Jul 21
[PubMed PMID: 22821554]
Level 3 (low-level) evidence